AstraZeneca's Cediranib Filing Withdrawal: CHMP Had Two Major Issues
Executive Summary
European filing for ovarian cancer candidate cediranib was undone by differences in opinion between AstraZeneca and EMA's CHMP advisory committee in two key areas – the clinical benefit, and compliance with GCP.